Starting Dose of Citalopram for a 71-Year-Old Patient
For a 71-year-old patient, start citalopram at 10 mg per day, with a maximum dose of 20 mg per day. This reduced dosing is mandated by FDA labeling due to age-related pharmacokinetic changes and increased risk of QT prolongation in older adults 1.
Dosing Algorithm for Older Adults
Initial Dosing
- Age >60 years: Start at 10 mg daily (can be taken morning or evening, with or without food)
- Maximum dose: 20 mg/day - doses above this are not recommended due to QT prolongation risk 1
Rationale for Age-Based Dose Reduction
The FDA labeling explicitly states that 20 mg/day is the maximum recommended dose for patients greater than 60 years of age 1. This restriction is based on pharmacokinetic studies showing:
- Citalopram AUC increased by 23-30% in subjects ≥60 years compared to younger subjects
- Half-life increased by 30-50% in older adults 1
- Research confirms steady-state levels in elderly patients receiving 20 mg daily can be up to four times higher than expected from younger patient data 2
- Plasma level-to-dose ratios are significantly elevated in older patients (3.50 vs 1.96 in younger patients) 3
Critical Safety Considerations
QT Prolongation Risk:
- Citalopram causes dose-dependent QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death at doses exceeding 40 mg/day 4
- For patients >60 years, this risk threshold is lowered to 20 mg/day 5, 1
- Avoid in patients with long QT syndrome 4
- Exercise caution with concomitant QT-prolonging medications 4
Additional Age-Related Risks:
- Elderly patients have greater risk for clinically significant hyponatremia with SSRIs 1
- SSRIs increase cardiac arrest risk (OR 1.21), with patients on SSRIs being older (mean age 74 years) 5
Titration Strategy
If starting at 10 mg daily proves insufficient after 4-8 weeks:
- Increase to 20 mg daily (maximum dose for this age group)
- Allow at least one week between dose changes 1
- Monitor for therapeutic benefit and adverse effects at each increment
Do not exceed 20 mg/day in patients >60 years - the evidence does not support higher doses providing additional benefit, and they substantially increase harm risk 1.
Monitoring Requirements
- Assess response using standardized symptom scales at 4-8 weeks
- Monitor for common SSRI side effects: nausea, sleep disturbances, dizziness, gastrointestinal symptoms 6
- Watch for hyponatremia symptoms, especially in first weeks of treatment
- Consider baseline ECG if cardiac risk factors present, given QT prolongation concerns 5
Common Pitfalls to Avoid
- Do not use standard adult dosing (20-40 mg) - this ignores FDA age-based restrictions and pharmacokinetic data
- Do not rapidly titrate - older adults require slower dose escalation due to altered drug metabolism 2, 3
- Avoid abrupt discontinuation - taper over 10-14 days to limit withdrawal symptoms 6, 1
- Check for drug interactions - citalopram interacts with other QT-prolonging drugs and has moderate CYP450 effects 4
Special Circumstances
Additional dose reductions to maximum 20 mg/day also required for:
- Hepatic impairment
- CYP2C19 poor metabolizers
- Concomitant use of cimetidine or CYP2C19 inhibitors 1
Severe renal impairment: Use with caution; no specific dose adjustment for mild-moderate renal impairment 1
The evidence consistently demonstrates that elderly patients achieve therapeutic plasma concentrations at lower doses due to reduced metabolic clearance 2, 3, making the conservative 10 mg starting dose with 20 mg maximum both pharmacologically sound and mandated by regulatory guidance.